After speaking with a breast surgical oncologist that performs nearly 1,000 procedures per year, Piper Jaffray analyst Matt O'Brien says Merit Medical Systems remains his favorite mid cap name. The analyst keeps an Overweight rating on the shares with a $58 price target. The doctor users Merti's Savi Scout product in nearly all of her cases and noted significant patient benefits including aesthetics and comfort, O'Brien tells investors in a research note. He believes Savi Scout's benefits are even more pronounced for physicians from an ease-of-use perspective, along with removing more diseased tissue than the traditional wires while preserving healthy tissue. O'Brien thinks the Scout product will contribute meaningfully to Merit Medical's growth and gross margin expansion going forward.